VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy

NCT05920343 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Venous Thromboembolism
Urologic Cancer

Interventions

DRUG: Rivaroxaban 10 MG
OTHER: Placebo control

Sponsor

Ottawa Hospital Research Institute

Collaborators

[object Object]
[object Object]
[object Object]